Clinical Trials Logo

Venous Thromboembolism clinical trials

View clinical trials related to Venous Thromboembolism.

Filter by:

NCT ID: NCT02832947 Completed - Clinical trials for Prophylaxis of Venous Thromboembolism

PK of Rivaroxaban in Bariatric Patients - Extension

Start date: February 2016
Phase: Phase 1
Study type: Interventional

Aim of this clinical Trial is the assessment of rivaroxaban PK/PD parameters in patients 6-8 months after bariatric surgery

NCT ID: NCT02829957 Completed - Clinical trials for Venous Thromboembolism

RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding

(RAMBLE)
Start date: September 2016
Phase: Phase 2/Phase 3
Study type: Interventional

A large proportion of women with menstruating potential with newly diagnosed VTE or atrial fibrillation, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.

NCT ID: NCT02828904 Completed - Clinical trials for Venous Thromboembolism

RIVET - Retrospective Cohort Study on the Risk of Venous Thromboembolism

RIVET-RCS
Start date: March 10, 2022
Phase:
Study type: Observational

The risk of venous thromboembolism (VTE) associated with the use of chlormadinone acetate (CMA) compared to the gold-standard progestin levonorgestrel (LNG) as component of combined oral contraceptives (COC) is currently unknown. The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) recommended a pooled analysis of four prospective cohort studies carried out by the Berlin Center for Epidemiology and Health Research (ZEG Berlin) in order to clarify whether CMA-containing COCs carry a different VTE risk compared to LNG-containing COCs.

NCT ID: NCT02798471 Completed - Pulmonary Embolism Clinical Trials

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

Start date: March 27, 2017
Phase: Phase 3
Study type: Interventional

This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in pediatric subjects with confirmed VTE.

NCT ID: NCT02795065 Completed - Clinical trials for Venous Thromboembolism

Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients

Start date: March 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to compare two types of low-molecular-weight heparin, enoxaparin and bemiparin, as regards their efficacy and safety in venous thromboembolism prevention among intensive care unit patients.

NCT ID: NCT02774265 Completed - Pulmonary Embolism Clinical Trials

A Different Approach to Preventing Thrombosis

ADAPT
Start date: January 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to perform a pragmatic randomized controlled trial to compare the use of low molecular weight heparin (LMWH, lovenox, enoxaparin) versus acetylsalicylic acid (ASA) for venous thromboembolism (VTE) prophylaxis in patients with high-risk lower extremity fractures.

NCT ID: NCT02746185 Completed - Clinical trials for Venous Thromboembolism

Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban

CASTA-DIVA
Start date: September 2016
Phase: Phase 3
Study type: Interventional

The study will compare the efficacy and safety of oral rivaroxaban and subcutaneous dalteparin in patients with cancer associated thrombosis. It is designed as a non-inferiority open label randomized multicenter trial with blinded adjudication of outcome events.

NCT ID: NCT02744092 Completed - Cancer Clinical Trials

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

CANVAS
Start date: December 13, 2016
Phase: N/A
Study type: Interventional

The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin. The information gained will empower cancer patients and physicians to make more informed choices about anticoagulation strategies to manage VTE.

NCT ID: NCT02742623 Completed - Clinical trials for Venous Thrombosis and Pulmonary Embolism

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer

COSIMO
Start date: October 11, 2016
Phase:
Study type: Observational

This study aims to collect patient reported outcomes and assess treatment satisfaction in active cancer patients treated with rivaroxaban for VTE (venous thromboembolism).

NCT ID: NCT02739867 Completed - Neoplasms Clinical Trials

Tumor-educated Platelets in Venous Thromboembolism

Start date: June 2016
Phase:
Study type: Observational

Among patients with a first episode of unprovoked venous thromboembolism (VTE), the contemporary one-year risk of detecting occult cancer is approximately 4% to 7%. Of these cases, 30% to 60% are missed by routine limited screening for cancer. RNA profiling of platelets is a promising, highly accurate biomarker for cancer detection, but its clinical utility in patients with unprovoked VTE is unknown. The objective of the present study is to evaluate the diagnostic accuracy of platelet RNA profiling in detecting occult cancer in patients with unprovoked venous thromboembolism. Secondary objectives include evaluation of other biomarkers for cancer, prediction of bleeding, and prediction of recurrent VTE.